In this article, we explore the 10 Popular Penny Stocks on Robinhood to Buy.
Robinhood is a FINRA and SEC-regulated broker. It plays the role of a bridge that routes customer orders to market makers and exchanges. The firm was founded to “Democratize finance for all,” and has evolved from a commission-free trading pioneer into what analysts now describe as a diversified financial SuperApp. As of February 2026, the platform had a little over 27 million registered paying users and total platform assets of $314 billion. Robinhood lets customers trade stocks, options, futures, and crypto, and it also offers retirement accounts and professionally managed portfolios.
That democratizing impulse has been Robinhood’s most enduring achievement; it has expanded market participation to include opportunities across the full spectrum, including penny stocks. Investors often refer to shares trading below $5 as penny stocks. These companies also fall within the small-cap category.
Small caps kicked off this year with a bang. Between October 2025 and March 06, 2026, small caps returned 10% while the S&P 500 remained flat, a Barron’s analysis shows. The analysis added that trailing 12-month earnings for the S&P 600 small-cap index were up nearly 30% over the same period, which was a reversal after nearly three years of declines. According to CNBC, the reversal came on the back of fears of an energy price-driven inflation uptick, which caused traders to dial up expectations of a Federal Reserve rate rise.
The turbulence was set off by tensions in the Middle East, which spiked oil prices and stoked recession fears. A turnaround, however, may be in the offing. President Trump announced on March 23 that the US and Iran have held “productive” talks, a development that sparked optimism on Wall Street that the market-roiling conflict could be nearing an end, according to the Wall Street Journal. MarketWatch noted that small caps led the ensuing relief rally. To Tim Pagliara, investing chief at CapWealth, the “stock market can recover well before the conflict in Iran ends.” Interestingly, this is not an isolated sentiment because Jay Woods, chief market strategist at Freedom Capital Markets and a longtime NYSE insider, said the market will attempt to reclaim lost ground. And when it does, investors should watch small-cap stocks closely, Woods told CNBC.
Against this background, this article explores some of the popular penny stocks that Robinhood offers buying opportunities for.
Our Methodology
To compile our list of the 10 Popular Penny Stocks on Robinhood to Buy, we used the Finviz stock screener to build an initial pool of stocks trading below $5 with an analyst consensus upside potential of more than 50% as of March 25, 2026. We further filtered this pool for stocks with an average daily trading volume of more than 2 million shares over the most recent three-month period, which is a proxy for popularity, and confirmed that each stock is available for trading on Robinhood. We further validated each selection using hedge fund holdings data from Insider Monkey’s Q4 2025 13F database to assess institutional interest. The final list is ranked in ascending order based on average daily trading volume over the past three months.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
Popular Penny Stocks on Robinhood to Buy
10. MannKind Corporation (NASDAQ:MNKD)
Average Daily Trading Volume: 5.69 million shares
Stock Price: $2.29
Stock Upside: 205.68%
Number of Hedge Fund Holding: 39
MannKind Corporation (NASDAQ:MNKD) is one of the popular penny stocks on Robinhood to buy. On March 11, MannKind Corporation CEO Michael Castagna and CFO Chris Prentiss presented at the Barclays 28th Annual Global Healthcare Conference in Miami. The executives walked analysts through the company’s evolution from a single-revenue inhaled insulin business into a diversified, commercial-stage specialty pharma company. They also outlined what they expect to drive the next phase of growth.
According to the presentation, the most pressing near-term catalyst is the United Therapeutics, or UT, partnership, which had recently drawn market concern. Castagna addressed this directly, noting that following a meeting with UT, the company received reassurance that Tyvaso DPI remains central to UT’s future growth plans. The CEO added that MannKind has since learned it will be the primary, not backup, supplier for Tyvaso DPI. This means the minimum revenue floor under the supply agreement will be meaningfully higher than originally modeled.
Castagna also confirmed that MannKind and UT are collaborating on a second undisclosed compound. As part of the deal, MannKind will earn a 10% royalty on that product as well if and when it receives FDA approval.
The presentation detailed that MannKind completed its $360 million acquisition of scPharmaceuticals in October 2025. As such, FUROSCIX, a treatment for fluid overload in chronic heart failure and chronic kidney disease patients, is now part of the company’s products. This opens a new cardiometabolic business unit alongside MannKind’s existing orphan lung division, the CEO noted.
FUROSCIX generated $70 million in revenue in 2025, and management believes the $110-$120 million revenue target tied to the deal’s contingent value right is achievable in 2026. Analysts had previously modeled peak sales at $500 million, but Castagna called that figure a starting point, not a peak.
MannKind Corporation is a biopharmaceutical company that develops and commercializes treatments for diabetes and lung diseases. Its main product is Afrezza, an inhaled insulin therapy for adults with type 1 and type 2 diabetes, and it also co-develops Tyvaso DPI for pulmonary arterial hypertension.
9. CytomX Therapeutics Inc. (NASDAQ:CTMX)
Average Daily Trading Volume: 6.26 million shares
Stock Price: $4.24
Stock Upside: 183.02%
Number of Hedge Fund Holding: 33
CytomX Therapeutics Inc. (NASDAQ:CTMX) is one of the popular penny stocks on Robinhood to buy. On March 23, Piper Sandler analyst Joseph Catanzaro raised his price target on CytomX Therapeutics Inc. to $12 from $10, while maintaining an Overweight rating. This move followed encouraging Phase 1 clinical data from CytomX’s lead drug candidate, varsetatug maseatecan, or varseta-M.
Catanzaro noted that the data from CytomX’s lead drug candidate test showed dose-dependent efficacy. In particular, the 10mg/kg dose delivered a 32% objective response rate and an 84% disease control rate.
Building on those results, CytomX has launched a Phase Ib study combining varseta-M with Avastin, or bevacizumab, the analyst noted. The company is planning to start a separate Phase Ib/II trial combining Avastin with chemotherapy in earlier-line colorectal cancer patients. Catanzaro noted that this is a sign the company is moving the drug up the treatment ladder rather than keeping it confined to late-stage patients.
The analyst also noted that CytomX is preparing to present Phase 1 data on CX-801 combined with Merck’s KEYTRUDA in advanced melanoma patients by the end of 2026. This, said Catanzaro, adds a second clinical catalyst to the pipeline calendar.
Separately, on the balance sheet, CytomX ended 2025 with $137 million in cash. The company then raised an additional $250 million through a stock offering where it priced 47.2 million shares and pre-funded warrants at $5.30 per share. This brought pro forma cash to approximately $372 million and gave the company ample runway to fund its ongoing and planned trials.
CytomX Therapeutics Inc. is a clinical-stage biopharmaceutical company that develops antibody-based therapies for cancer treatment. Its proprietary Probody technology is designed to localize therapeutic activity to tumor tissue while minimizing effects on healthy cells.
8. Genius Sports Limited (NYSE:GENI)
Average Daily Trading Volume: 6.60 million shares
Stock Price: $4.54
Stock Upside: 153.30%
Number of Hedge Fund Holding: 41
Genius Sports Limited (NYSE:GENI) is one of the popular penny stocks on Robinhood to buy. On March 24, the Public Health Advocacy Institute, or PHAI, filed a product liability lawsuit in the Philadelphia County Court of Common Pleas against Genius Sports Limited, DraftKings (NASDAQ:DKNG), Flutter Entertainment’s (NYSE:FLUT) FanDuel, the National Football League (NFL), and five individual sportsbook employees. The lawsuit is on behalf of two Pennsylvania men who allege they developed severe gambling addictions after using the DraftKings and FanDuel apps.
The lawsuit identified microbetting as the key issue. Microbetting is rapid, in-game wagering on granular real-time events such as the next play in a football game or the next pitch in baseball. According to the complaint, this product, microbetting, is deliberately engineered for addiction. The fact that it is powered by artificial intelligence, machine learning, and cloud computing to identify and exploit each user’s behavioral vulnerabilities makes it worse, the lawsuit claims.
Genius Sports is named because it serves as the sole supplier of the NFL’s official live data and statistics to online sportsbooks. By its own description, Genius Sports powers over 98% of the legalized US sports betting market with that NFL data.
In a separate update, on March 13, Benchmark analyst Mike Hickey maintained a Buy rating and $10 price target on Genius Sports. The decision followed a new US regulatory development that directly reinforces the company’s core business model.
The analyst stated that the trigger was a March 12 advisory from the CFTC that recommended that designated contract markets use official data provided by sports leagues or governing bodies as the settlement source for sports event contracts. This means that data is verified and authenticated at the source and not aggregated from third parties. Hickey described this as a move that “formalizes regulatory preference around official feeds as manipulation-resistant benchmarks.”
Genius Sports Limited is a sports data and technology company. It provides data collection, distribution, and integrity services to sports leagues and betting operators. Its offerings include live data feeds, video streaming, and digital marketing solutions.
7. Ocugen Inc. (NASDAQ:OCGN)
Average Daily Trading Volume: 7.69 million shares
Stock Price: $1.92
Stock Upside: 316.67%
Number of Hedge Fund Holding: 14
Ocugen Inc. (NASDAQ:OCGN) is one of the popular penny stocks on Robinhood to buy. On March 2, Ocugen, Inc. announced the completion of patient enrollment for its Phase 3 liMeliGhT clinical trial. The trial is for evaluating OCU400, an investigational modifier gene therapy for retinitis pigmentosa, or RP. RP is a hereditary blinding disease.
According to Ocugen, the enrollment completion marks the transition from recruitment into the final phase of the trial ahead of a targeted 2027 approval. The trial enrolled 140 patients, randomized at a 2:1 ratio into a treatment group and an untreated control group, the company detailed. It added that the trial covers a broad range of RP gene mutations.
OCU400 is administered as a single injection per eye, Ocugen stated. The treatment works by targeting the NR2E3 nuclear hormone receptor gene, which regulates multiple retinal functions including photoreceptor development and cell survival. Rather than correcting a single mutation, Ocugen explained, the treatment aims to restore a dysfunctional gene network at the cellular level. This is what makes OCU400 gene-agnostic, which means it is designed to work across different genetic causes of RP rather than being limited to one specific mutation.
The trial’s primary endpoint is a 12-month change in visual function assessed by Luminance Dependent Navigation Assessment, or LDNA. This is a proprietary Ocugen mobility test measuring improvement in Lux Level from baseline. Ocugen expects topline data from this one-year trial in Q1 calendar year 2027.
Ocugen Inc. is a biotechnology company. It focuses on developing therapies for eye diseases and gene therapies for rare disorders. Its pipeline includes OCU400, a modifier gene therapy for inherited retinal diseases, and OCU410, a treatment for dry age-related macular degeneration.
6. TMC the metals company Inc. (NASDAQ:TMC)
Average Daily Trading Volume: 7.85 million shares
Stock Price: $4.68
Stock Upside: 151.07%
Number of Hedge Fund Holding: 21
TMC the metals company Inc. (NASDAQ:TMC) is one of the popular penny stocks on Robinhood to buy. On March 9, TMC the metals company Inc. announced that the National Oceanic and Atmospheric Administration (NOAA) had determined that the consolidated deep-seabed mining application submitted by its US subsidiary, TMC USA LLC, is in substantial compliance with the requirements of the Deep Seabed Hard Mineral Resources Act. This means that the company is now closer to commencing to commercially mine polymetallic nodules in the Pacific Ocean.
TMC USA filed the consolidated application earlier this year, and it covers an approximately 65,000 square kilometer exploration and commercial recovery area in the Clarion Clipperton Zone, or CCZ. This is a stretch of the Pacific seafloor between Hawaii and Mexico. TMC USA’s initial commercial recovery permit application, filed in April 2025, only covered around 25,000 square kilometers. According to the press release, the expanded area contains an estimated 619 million tons of wet polymetallic nodules, and that there is potential for an additional 200 million tons from exploration upside.
The nodules on the seafloor contain critical metals including nickel, cobalt, copper, and manganese. These materials, said TMC, are central to battery production, defense systems, clean energy infrastructure, and advanced electronics. As such, the CCZ is now at the heart of the global critical minerals race, noted TMC.
TMC the metals company Inc. is a deep-sea minerals exploration company. It focuses on sourcing battery metals from polymetallic nodules found on the ocean floor. Its operations target critical resources such as nickel, cobalt, copper, and manganese.
5. SEALSQ Corp (NASDAQ:LAES)
Average Daily Trading Volume: 7.95 million shares
Stock Price: $2.88
Stock Upside: 160.42%
Number of Hedge Fund Holding: 6
SEALSQ Corp (NASDAQ:LAES) is one of the popular penny stocks on Robinhood to buy. On March 24, SEALSQ Corp signed a Letter of Intent (LOI) to acquire 100% of Miraex SA, a photonics-based quantum interconnect company.
According to a press release, the LOI grants SEALSQ a 60-day exclusivity window to conduct confirmatory due diligence and negotiate binding transaction documents. SEALSQ noted that the deal is binding on Miraex’s side. The company expects the acquisition to close by the end of June this year after satisfying all regulatory approvals and customary closing conditions. The transaction will be funded through the SEALSQ Quantum Fund, the company said.
Source: pexels
Miraex’s core technology connects quantum processors to quantum networks. SEALSQ noted that this is one of the most difficult engineering problems in quantum computing. The technology achieves the feat through a Photonic Integrated Circuit platform built on Thin Film Lithium Tantalate. This material enables the conversion of signals between microwave and optical frequencies. This microwave-to-optical transduction is a foundational requirement for any distributed quantum architecture.
SEALSQ CEO Carlos Moreira framed the deal as completing a missing layer in the company’s Quantum Vertical Stack. “Their photonics-based quantum interconnect solutions are not just complementary to our roadmap, they form a critical interconnect layer linking our quantum computing, quantum networking, and post-quantum cryptography capabilities into a more coherent architecture,” Moreira said.
Beyond the immediate stack, SEALSQ expects the acquisition to accelerate its Quantum Spatial Orbital Cloud initiative. This is the company’s flagship program to deploy quantum-secure capabilities across Low Earth Orbit satellites and terrestrial environments.
SEALSQ Corp, a subsidiary of WISeKey International Holding Ltd (NASDAQ:WKEY), is a semiconductor company. It designs and manufactures secure microcontrollers and chips for applications in cybersecurity, artificial intelligence, and the Internet of Things. Its products include secure elements, cryptographic chips, and related software solutions that enable authentication and data protection across connected devices.
4. SELLAS Life Sciences Group Inc. (NASDAQ:SLS)
Average Daily Trading Volume: 9.32 million shares
Stock Price: $5.00
Stock Upside: 100.20%
Number of Hedge Fund Holding: 6
SELLAS Life Sciences Group Inc. (NASDAQ:SLS) is one of the popular penny stocks on Robinhood to buy. On March 17, SELLAS Life Sciences Group, Inc. announced that it will present preclinical data on SLS009 at the American Association for Cancer Research annual meeting on April 21, 2026.
SLS009, alternatively known as tambiciclib, is a selective CDK9 inhibitor. Put simply, this is a treatment designed to stop a specific “worker” protein in human cells called CDK9. SELLAS said it will present the data in a poster session. That is, instead of giving a formal speech on the stage at the San Diego Convention Center, the company will only display a printed poster.
The poster, titled “Tambiciclib (SLS009), a CDK9 inhibitor, promotes apoptosis and suppresses MCL-1 levels in AML cell lines,” centers on the drug’s mechanism of action in acute myeloid leukemia, or AML, the company said in a press release statement. According to preclinical data, said SELLAS, SLS009 retained its activity in AML models carrying ASXL1 and TP53 mutations. To the company’s experts, this behavior underscores the drug’s potential to address patient populations that currently have very limited treatment options.
Earlier on March 12, SELLAS enrolled its first patient in a newly diagnosed, first-line AML trial of SLS009 in combination with venetoclax and azacitidine. This came after the FDA guidance that recommended this expansion after the drug met all endpoints in its completed Phase 2 trial in relapsed/refractory (r/r) AML. In the trial, the drug exceeded the pre-specified 20% overall response rate threshold with favorable safety and tolerability.
SELLAS Life Sciences Group Inc. is a clinical-stage biopharmaceutical company that develops cancer immunotherapies. Its lead product candidate is galinpepimut-S, a peptide-based immunotherapy designed to treat hematologic cancers and solid tumors.
3. HIVE Digital Technologies Ltd. (NASDAQ:HIVE)
Average Daily Trading Volume: 10.73 million shares
Stock Price: $2.05
Stock Upside: 168.29%
Number of Hedge Fund Holding: 14
HIVE Digital Technologies Ltd. (NASDAQ:HIVE) is one of the popular penny stocks on Robinhood to buy. On March 15, HIVE Digital Technologies Ltd. announced that its wholly owned subsidiary BUZZ HPC, is expanding its liquid-cooled AI data center footprint into British Columbia (BC), Canada. The move will quadruple the company’s Canadian critical IT load capacity to a total of 16.6 megawatts through a new colocation partnership with Bell Canada AI Fabric.
The BC expansion will be in two phases. Phase 1 will deliver an immediate 5 megawatts of critical IT load, which will support the deployment of up to 2,000 next-generation, high-power-density, AI-optimized GPUs in the province. Phase 2 will enable HIVE to scale an additional 7.6 megawatts in 2027. This will support a further 3,000 GPUs and bring the total BC potential to 12.6 megawatts and over 5,000 GPUs from that location alone.
The company noted that the BC capacity complements BUZZ’s existing Manitoba facility, which carries 4 megawatts of critical IT load. Of that, 504 next-generation GPUs consuming approximately 1 megawatt are already live. Three megawatts of remaining capacity is available for roughly 1,500 additional GPUs. Combined, HIVE now has a near-term path to deploying over 4,000 GPUs across two Canadian provinces. In the longer-term, the company anticipates to deploy over 6,000 GPUs in Canada.
HIVE Digital Technologies Ltd. is a blockchain infrastructure company. It operates data centers for cryptocurrency mining and high‑performance computing. Its facilities mine digital assets such as bitcoin and Ethereum using renewable energy sources. They also provide computing capacity for artificial intelligence and other applications.
2. American Bitcoin Corp. (NASDAQ:ABTC)
Average Daily Trading Volume: 13.62 million shares
Stock Price: $0.95
Stock Upside: 321.45%
Number of Hedge Fund Holding: 7
American Bitcoin Corp. (NASDAQ:ABTC) is one of the popular penny stocks on Robinhood to buy. On March 3, American Bitcoin Corp. announced the purchase of 11,298 new Bitcoin miners. The company expects the miners, also called ASICs, or Application-Specific Integrated Circuits, to add approximately 3.05 Exahash per second (EH/s) of hashing power at an efficiency of around 13.5 Joules per Terahash (J/TH). This will expand the company’s total owned fleet by 12% to 89,242 miners, around 28.1 EH/s of owned capacity.
The company detailed that it will take delivery of the new machines within this month, March 2026. It will deploy the machines, also within this month, at the company’s Drumheller facility in Alberta, Canada. Once online, the active working fleet, which excludes units not yet operational, will reach 58,999 miners delivering roughly 25.0 EH/s at an improved average efficiency of about 14.1 J/TH, the company said in a press release statement. In comparison, the current full-fleet average is approximately 16.0 J/TH, which means the new units are measurably more power-efficient than the existing base.
Eric Trump, the company’s Co-Founder and Chief Strategy Officer, noted that the expansion comes at a moment when many competing mining firms are redirecting capital away from Bitcoin mining. American Bitcoin will not follow this trend, Trump stated. He said: “As Bitcoin matures, the priority is clear: grow American-owned, professionally operated hashrate. That’s how we protect the network, drive innovation, and lead the future of Bitcoin in America.”
American Bitcoin Corp. is a cryptocurrency mining company that develops and operates facilities for bitcoin production. Its operations focus on industrial-scale mining infrastructure that leverages low-cost energy sources to generate bitcoin efficiently.
1. Bitfarms Ltd. (NASDAQ:BITF)
Average Daily Trading Volume: 35.63 million shares
Stock Price: $2.21
Stock Upside: 130.95%
Number of Hedge Fund Holding: 28
Bitfarms Ltd. (NASDAQ:BITF) is one of the popular penny stocks on Robinhood to buy. On March 20, Bitfarms Ltd. announced that shareholders had voted overwhelmingly to approve a statutory plan of arrangement authorizing the company to move operations back to the US from Canada. The company also received the green light to rebrand as Keel Infrastructure Corp.
The vote was held at a virtual Special Meeting of Shareholders, where the single agenda item was the Arrangement Resolution. This is a special resolution requiring approval by at least two-thirds of votes cast to pass. The resolution cleared that threshold after a positive vote from 99.3% of the votes cast.
The transfer of operations from Canada to the US, called redomiciliation in technical terms, is structured as a statutory plan of arrangement under Canadian law. It enables each existing Bitfarms common share to be exchanged on a one-for-one basis for a share of common stock in Keel Infrastructure Corp. Keel Infrastructure is a newly incorporated Delaware company, and whose ticker will be KEEL on both NASDAQ and the Toronto Stock Exchange, or TSX. Bitfarms anticipates the process will be completed on or about April 1, 2026, after satisfying the courts and other closing conditions.
CEO Ben Gagnon described the vote as the company’s entry into its next phase. He said: “Having conducted a thorough review of potential opportunities to enhance long-term shareholder value over the last year, the Board is confident this transition is the right path forward for our company as we complete our strategic pivot.”
Bitfarms Ltd. is a blockchain infrastructure company that operates data centers for cryptocurrency mining. Its facilities produce bitcoin using hydroelectric power in regions such as Québec, Paraguay, and Washington.
READ NEXT: 10 Robinhood Stocks with High Potential and 15 Best Forever Stocks to Buy Now.
Hedge Fund Resource Center